Beyondspring (BYSI) vs. Its Competitors Financial Comparison
Beyondspring (NASDAQ: BYSI) is one of 188 public companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its competitors? We will compare Beyondspring to similar businesses based on the strength of its profitability, risk, valuation, analyst recommendations, institutional ownership, dividends and earnings.
Earnings & Valuation
This table compares Beyondspring and its competitors revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Beyondspring Competitors||$217.29 million||-$39.39 million||-65.49|
This is a breakdown of recent ratings for Beyondspring and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Beyondspring presently has a consensus price target of $54.50, indicating a potential upside of 60.29%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 14.14%. Given Beyondspring’s stronger consensus rating and higher probable upside, research analysts plainly believe Beyondspring is more favorable than its competitors.
This table compares Beyondspring and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional and Insider Ownership
1.2% of Beyondspring shares are owned by institutional investors. Comparatively, 50.0% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 14.7% of shares of all “Biotechnology & Medical Research” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Beyondspring beats its competitors on 7 of the 11 factors compared.
BeyondSpring Inc. is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC). Plinabulin has also entered in a Phase I/II clinical trials to investigate its therapeutic potential in combination with the immuno-oncology agent nivolumab. The Company’s BPI-002 program is based on an oral small molecule agent, which induces T-cell activation. The Company’s IkappaB kinase (IKK) program, BPI-003, is based on a small molecule inhibitor of IKK, a protein kinase.
Receive News & Ratings for Beyondspring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beyondspring and related companies with MarketBeat.com's FREE daily email newsletter.